Compare Invesco DB Agriculture Fund (DBA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs State Street SPDR S&P Biotech ETF — how do they compare? Invesco DB Agriculture Fund trades at $28.33 (market cap $1.32B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 7.7× Invesco DB Agriculture Fund's market cap, and Invesco DB Agriculture Fund is more actively traded (771,657 versus 12,903,266). Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Agriculture Fund for 24 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| DBA | XBI | |
|---|---|---|
Market Cap | $1.32B | $10.11B |
Volume | 771,657 | 12,903,266 |
52-Week High | $29.49 | $169.55 |
52-Week Low | $25.44 | $104.99 |
Typical Hold Time | 24 Days | 38 Days |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA trades at $28.34, down 0.53% with a bearish technical signal from moving averages. The ETF has delivered strong YTD performance of 12.4%, matching the S&P 500, driven by agricultural commodity strength and geopolitical catalysts. Recent consolidation near highs reflects mixed sentiment with neutral oscillators but solid momentum indicators.
The agricultural ETF faces headwinds from high expense ratios (0.85%) and commodity volatility, but benefits from weather risks and global demand. Analyst consensus leans neutral with geopolitical developments and El Niño impacts presenting both opportunities and risks for continued outperformance in agricultural markets.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
